Amgen Inc (AMGN) Stock Price & Analysis
Amgen Inc (AMGN) rose 1.22% to USD 376.04 as of July 25, 2026 at 01:12 UTC, according to Nexqual real-time market data.
AMGN last closed at USD 371.5; the session ranged USD 372.16–379.41 on volume of 2,450,808 shares. Market capitalization is $202.95B, with a 52-week range of USD 269.77–391.29 (NMS). Source: Nexqual, July 25, 2026 at 01:12 UTC.
Key Statistics (as of July 25, 2026 at 01:12 UTC)
| Price | USD 376.04 |
|---|---|
| Change | ▲ 1.22% (up) |
| Previous Close | USD 371.5 |
| Open | USD 372.73 |
| Day Range | USD 372.16 – 379.41 |
| 52-Week Range | USD 269.77 – 391.29 |
| Volume | 2,450,808 shares |
| Market Cap | $202.95B |
| Exchange | NMS |
Technical Analysis (AMGN)
Nexqual's technical model rates AMGN "BUY" based on 5 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 01:12 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 62.55 (neutral) |
| vs SMA50 | Above (USD 350.23) |
| MACD | 5.38 (positive) |
Analyst Ratings (AMGN)
Wall Street analysts rate AMGN "Buy" based on 29 analysts, with a mean price target of USD 356.69 (range USD 215–427), per Nexqual as of July 25, 2026 at 01:12 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 29 |
| Mean Target | USD 356.69 |
| High Target | USD 427 |
| Low Target | USD 215 |
| Buy / Hold / Sell | 14 / 17 / 3 |
Earnings (AMGN)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD 5.62 |
| Revenue Estimate | $9.43B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 5.15 vs est 4.77 ▲ beat |
| 2025-12-31 | USD 5.29 vs est 4.73 ▲ beat |
| 2025-09-30 | USD 5.64 vs est 5.01 ▲ beat |
| 2025-06-30 | USD 6.02 vs est 5.28 ▲ beat |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
Financials & Fundamentals (AMGN)
| Total Revenue | $37.22B |
|---|---|
| Revenue Growth (YoY) | +5.80% |
| Gross Margin | +71.44% |
| Operating Margin | +33.80% |
| Profit Margin | +20.96% |
| ROE | +101.32% |
| Debt / Equity | 623.75 |
| Current Ratio | 1.26 |
| Total Cash | $12.04B |
| Total Debt | $57.32B |
| Free Cash Flow | $7.44B |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
Financial Health Score (AMGN)
Nexqual rates Amgen Inc's overall financial health "Solid" across five dimensions, as of July 25, 2026 at 01:12 UTC.
| Growth | Solid — Revenue +10% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 71%, operating 34% |
| Balance Sheet | Critical — $12.0B cash vs $57.3B debt |
| Cash Flow | Strong — FCF $7.44B, 20% margin |
| Efficiency | Strong — ROE 101%, ROA 8.3% |
Ownership (AMGN)
| Insider Ownership | +0.22% |
|---|---|
| Institutional Ownership | +87.24% |
| Shares Outstanding | 539.71M |
| Float | 538.22M |
| Short % of Float | +2.39% |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
Leadership (AMGN)
Amgen Inc is led by Robert A. Bradway (age 62), Chairman & CEO, per Nexqual as of July 25, 2026 at 01:12 UTC.
| Chairman & CEO | Robert A. Bradway (age 62) |
|---|---|
| Executive VP & CFO | Peter H. Griffith (age 66) |
| Executive Vice President of Global Markets and Policy | Murdo Gordon (age 58) |
| Executive Vice President of Operations | Esteban Santos (age 57) |
| SVP & Chief Technology Officer | Sean Bruich |
Major Backers & Investors (AMGN)
Notable institutional backers of Amgen Inc include Capital Group, Invesco, Morgan Stanley, according to Nexqual as of July 25, 2026 at 01:12 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Capital Group | 5.43% |
| Invesco | 5.06% |
| Morgan Stanley | 2.93% |
| Charles Schwab Investment Management, Inc. | 2.37% |
| Primecap Management Company | 1.64% |
| Charles Schwab | 1.61% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 14.91% |
| BlackRock | 10.04% |
| State Street | 6.87% |
| Geode Capital | 2.86% |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
From Amgen Inc's Latest SEC 10-K Filing (filed 2026-02-13)
Key Strengths & Strategy (as disclosed to the SEC)
- Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
- It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI.
- The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies.
- It distributes its products through pharmaceutical wholesale distributors.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BIIB | Biogen Inc. | USD 202.19 | ▲ 2.25% |
| GILD | Gilead Sciences, Inc. | USD 129.31 | ▼ 0.79% |
| BMY | Bristol-Myers Squibb Company | USD 62.09 | ▲ 2.19% |
| MRK | Merck & Company, Inc. | USD 131.07 | ▲ 2.82% |
| LLY | Eli Lilly and Company | USD 1,196.03 | ▲ 2.84% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:12 UTC. This page is informational and not investment advice.